Regenerative Medicine

Regenerative healing restores the body to the same level of function as it had prior to injury or disease. By the 1970’s, science was beginning to document observations that fetuses in early gestation experienced a healing process vastly different than what is experienced outside of the womb.2,3 With the advent of in utero surgery in the 1980’s, direct observation of clinical outcomes of fetal healing demonstrated that it was regenerative in nature.  Research has shown that this occurs because the placental tissues, particularly the umbilical cord and amniotic membrane, have innate healing properties. More importantly, these properties can be preserved and transplanted to other environments to promote healing.

When processed appropriately, allograft birth tissue retains these properties and effectively applies them to unrelated hosts.4,5,6 The transplantation of this biology into mature tissue provides a means of disrupting the inflammatory cycle of repair inherent to adult tissue and drives a process of restorative and regenerative repair.   With more than 30 years of National Institute of Health funded research efforts, TissueTech has developed and commercialized proprietary technology that preserves the innate properties of the umbilical cord and amniotic membrane. The preservation of these key components provides allografts that promote the modulation of inflammation to support healing without the formation of scar tissue or adhesions and to minimize the pain that is customarily associated with such inflammation.

TissueTech is the first company to provide cryopreserved amniotic membrane and umbilical cord products to the market. The Company’s groundbreaking scientific research in regenerative medicine will support continued development of innovative cellular and tissue-based drug and biologic products. to treat an ever-broadening array of clinical conditions. More than 300,000 TissueTech allografts have been transplanted to date, benefitting hundreds of thousands of patients.

TissueTech has been awarded more than 30 US patents and numerous patents issued by other countries, covering CryoTek, SteriTek, cellular regeneration, advanced forms of and delivery methods for human amniotic membrane and umbilical cord, and other cutting-edge technologies.

References

The Star, Christchurch NZ Issue 8668 7 July 1906
Somasundaram K et al. J Pathol  (1970) 100:81-86
Rowlatt U. Virchows Arch. (1979)381: 353-361
Dua H et al. Surv Opthalmol  (2004) 49: 51-77
Bouchard et al. Ocul Surf  (2004) 2: 201-211
Tseng S et al. Ocul Surf  (2004)  2:177-187